In a heartbreaking turn of events, the parents of Karunya, who tragically passed away in 2021 after allegedly receiving the Covishield vaccine, are seeking legal recourse. Her grieving father, Venugopalan Govindan, blames multiple parties for his daughter's death and is determined to hold them accountable ..read more

Union government's high-level meeting aims to address the issue of substandard glove imports from Southeast Asia, focusing on implementing quality control orders for surgical gloves to ensure better standards in the domestic market ..read more

NephroPlus, India's largest dialysis chain, has secured $103 million (₹860 crore) in a Series F funding round led by Quadria Capital. This funding, a mix of fresh capital and a secondary sale, aims to drive expansion plans within India and targeted markets overseas. The primary component of the funding is ₹100 crore. Quadria Capital will become a minority shareholder, valuing NephroPlus at over ₹2,000 crore. Existing investors like Bessemer Venture Partners, International Finance Corporation, and IIFL also participated in the funding round, reducing their stakes ..read more

Bharat Biotech has emphasized the safety of its Covaxin Covid vaccine, stating that it has shown excellent safety records with no vaccine-associated incidents such as blood clots or other serious side effects. The company highlighted that Covaxin was developed with a focus on safety first, followed by efficacy. It mentioned that Covaxin was extensively evaluated in more than 27,000 subjects during its licensure process and has been continuously monitored for safety by the health ministry ..read more

Bayer Pharmaceuticals Private Limited and Zydus Lifesciences Limited have concluded their joint venture, Bayer Zydus Pharma Private Limited (BZPPL), established in 2011 for pharmaceutical sales and marketing in India. Bayer is now acquiring full ownership of the entity as per pre-agreed terms. The joint venture successfully combined Zydus's Indian marketing expertise and distribution network with Bayer's global innovation, making strides in various therapeutic areas ..read more

Maiva Pharma has raised Rs 1,000 crore from Morgan Stanley Private Equity Asia and India Life Sciences Fund, including both primary and secondary funding. The funds will be used to set up a new manufacturing facility near Karnataka's Hosur, with capabilities in sterile dosage forms, including pre-filled syringes, bags, oncology, and hormonal injectables. Maiva's complex injectables development and manufacturing capability, strong compliance and regulatory standards, and transparency differentiate the company from competitors ..read more

Morgan Stanley PE Asia and India Life Sciences Fund are investing almost equally, total stake with both funds combined will be over 60% post primary investment, the company told ET ..read more

AstraZeneca's admission of Covishield's potential link to Thrombosis with Thrombocytopenia Syndrome (TTS) has stirred concerns. Despite its rarity, social media debates over vaccine safety persist. Covishield, similar to AstraZeneca's, faces scrutiny, though TTS isn't exclusive to them. Here are all the answers about your doubts related to the recent controversy over AstraZeneca's Covishield ..read more

A plea has been filed seeking setting up of an expert medical panel to study and assess the possible risk factors associated with the Astrazeneca's Covishield vaccine, which was one of two vaccines administered in India against Covid-19. Advocate Vishal Tiwari in his fresh application said that AstraZeneca had accepted a link between the vaccine and Thrombosis with Thrombocytopenia Syndrome (TTS ..read more

..read more